Effect of off‐label targeted drugs on long‐term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry
Respirology · 2024
DOI: 10.1111/resp.14700 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Respirology, 2024. Verfasst von Wanying Xia und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Vascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking…. Hauptthemen laut MEDLINE: Registries, Off-Label Use, Hypertension, Pulmonary, Antihypertensive Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: China Key Research Projects of the 11th National Five-Year Development Plan, China Key Research Projects of the 12th National Five-Year Development Plan, National Key Research and Development Program of China.
Abstract (Originalsprache)
Background and Objective Off‐label pulmonary arterial hypertension (PAH)‐targeted drugs are commonly prescribed for non‐operated chronic thromboembolic pulmonary hypertension (CTEPH), but their effect on the long‐term prognosis of CTEPH remains unknown. This study investigated the effect of off‐label PAH‐targeted drugs on the long‐term survival of CTEPH patients.
Methods
CTEPH patients were enrolled from a prospective multicentre national registry. Except for licensed riociguat and treprostinil, other PAH‐targeted drugs were off‐label. In the original and propensity score–matched (PSM) samples, five‐year survival was compared in two groups: (a) patients not receiving off‐label PAH‐targeted drugs (control) versus (b) patients receiving off‐label PAH‐targeted drugs (treatment). The latter group was investigated for the effect of started off‐label PAH‐targeted drugs at baselines (initial) or during follow‐up (subsequent).
Results
Of 347 enrolled patients, 212 were treated with off‐label PAH‐targeted drugs initially ( n = 173) or subsequently ( n = 39), and 135 were untreated. The 1‐, 2‐, 3‐ and 5‐year survival of the treatment group was significantly higher than that of the control group (97.1% vs. 89.4%, 92.3% vs. 82.1%, 83.2% vs. 75.1% and 71.1% vs. 55.3%, respectively, log‐rank test, p = 0.005). Initial treatment was correlated with better 5‐year survival after excluding patients with subsequent treatment to reduce the immortal‐time bias (hazard ratio: 0.611; 95% CI: 0.397–0.940; p = 0.025). In PSM samples, patients given initial treatment showed significantly better 5‐year survival than untreated patients (68.9% vs. 49.3%, log‐rank test, p = 0.008).
Conclusion
Off‐label targeted drugs contributed to improved long‐term survival in CTEPH patients receiving pharmacotherapies. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Vascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, State Key Laboratory of Cardiovascular Disease…
- Respiratory and Critical Care Medicine, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
- Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
- Department of Peripheral Vascular Diseases, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
- Department of Respiratory Medicine, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
- Department of Cardiology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
ORCID-Profile: Wanying Xia, Ruilin Quan, Jianguo He
Förderung
- China Key Research Projects of the 11th National Five-Year Development Plan
- China Key Research Projects of the 12th National Five-Year Development Plan
- National Key Research and Development Program of China
Zitieren
APA
Xia, W., Qian, Y., Lin, Y., Quan, R., Yang, Y., Yang, Z., Tian, H., Li, S., Shen, J., Ji, Y., Gu, Q., Han, H., Xiong, C., & He, J. (2024). Effect of off‐label targeted drugs on long‐term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry. Respirology. https://doi.org/10.1111/resp.14700
Vancouver
Xia W, Qian Y, Lin Y, Quan R, Yang Y, Yang Z, et al. Effect of off‐label targeted drugs on long‐term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry. Respirology. 2024. doi:10.1111/resp.14700
BibTeX
@article{Xia2024,
author = {Xia, Wanying and Qian, Yuling and Lin, Yangyi and Quan, Ruilin and Yang, Yuanhua and Yang, Zhenwen and Tian, Hongyan and Li, Shengqing and Shen, Jieyan and Ji, Yingqun and Gu, Qing and Han, Huijun and Xiong, Changming and He, Jianguo},
title = {Effect of off‐label targeted drugs on long‐term survival in chronic thromboembolic pulmonary hypertension: Insights from a national multicentre prospective registry},
journal = {Respirology},
year = {2024},
doi = {10.1111/resp.14700}
}
EUVIMED